Inauhzin(c) Inactivates c-Myc Independently of p53

References

• Dang C, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15:6479-83; PMID:19861459; http://dx.doi.org/10.1158/1078-0432.CCR-09-0889
   PubMed Web of Science ®Google Scholar
• Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012; 151:68-79; PMID:23021216; http://dx.doi.org/10.1016/j.cell.2012.08.033
   PubMed Web of Science ®Google Scholar
• Verbeek S, van Lohuizen M, van der Valk M, Domen J, Kraal G, Berns A. Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991; 11:1176-9; PMID:1990273
   PubMed Web of Science ®Google Scholar
• Soucek L, Whitfield J, Martins C, Finch A, Murphy D, Sodir N, Karnezis AN, Swigart LB, Nasi S, Evan GI. Modelling Myc inhibition as a cancer therapy. Nature 2008; 455:679-83; PMID:18716624; http://dx.doi.org/10.1038/nature07260
   PubMed Web of Science ®Google Scholar
• Sodir N, Swigart L, Karnezis A, Hanahan D, Evan G, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011; 25:907-16; PMID:21478273; http://dx.doi.org/10.1101/gad.2038411
   PubMed Web of Science ®Google Scholar
• Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999; 3:565-77; PMID:10360173; http://dx.doi.org/10.1016/S1097-2765(00)80350-0
   PubMed Web of Science ®Google Scholar
• Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297:102-4; PMID:12098700; http://dx.doi.org/10.1126/science.1071489
   PubMed Web of Science ®Google Scholar
• Flores I, Murphy D, Swigart L, Knies U, Evan G. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene 2004; 23:5923-30; PMID:15208685; http://dx.doi.org/10.1038/sj.onc.1207796
   PubMed Web of Science ®Google Scholar
• Felsher D, Bishop J. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999; 4:199-207; PMID:10488335; http://dx.doi.org/10.1016/S1097-2765(00)80367-6
   PubMed Web of Science ®Google Scholar
• Kim J, Chu J, Shen X, Wang J, Orkin S. An extended transcriptional network for pluripotency of embryonic stem cells. Cell 2008; 132:1049-61; PMID:18358816; http://dx.doi.org/10.1016/j.cell.2008.02.039
   PubMed Web of Science ®Google Scholar
• Wright J, Brown S, Cole M. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 2010; 30:1411-20; PMID:20065031; http://dx.doi.org/10.1128/MCB.01384-09
   PubMed Web of Science ®Google Scholar
• Pomerantz M, Ahmadiyeh N, Jia L, Herman P, Verzi M, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009; 41:882-4; PMID:19561607; http://dx.doi.org/10.1038/ng.403
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn L. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8:976-90; PMID:19029958; http://dx.doi.org/10.1038/nrc2231
   PubMed Web of Science ®Google Scholar
• Eilers M, Eisenman R. Myc's broad reach. Genes Dev 2008; 22:2755-66; PMID:18923074; http://dx.doi.org/10.1101/gad.1712408
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q, Meroueh SO, Lu H. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 2012; 4:298-312; PMID:22331558; http://dx.doi.org/10.1002/emmm.201100211
   PubMed Web of Science ®Google Scholar
• Liao JM, Zeng SX, Zhou X, Lu H. Global effect of inauhzin on human p53-responsive transcriptome. PloS One 2012; 7:e52172; PMID:23284922; http://dx.doi.org/10.1371/journal.pone.0052172
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Q, Zeng SX, Hao Q, Lu H. Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents. Neoplasia 2013; 15:523-34; PMID:23633924
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Q, Zeng SX, Zhang Y, Mayo LD, Lu H. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther 2012; 13:915-24; PMID:22785205; http://dx.doi.org/10.4161/cbt.20844
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhou X, Wu R, Mosley A, Zeng SX, Xing Z, Lu H. The role of IMP dehydrogenase 2 in Inauhzin-induced ribosomal stress. Elife 2014; 3; e03077; PMID:25347121
   PubMed Web of Science ®Google Scholar
• Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 2008; 28:4365-76; PMID:18426907; http://dx.doi.org/10.1128/MCB.01662-07
   PubMed Web of Science ®Google Scholar
• Lo D, Dai MS, Sun XX, Zeng SX, Lu H. Ubiquitin- and MDM2 E3 ligase-independent proteasomal turnover of nucleostemin in response to GTP depletion. J Biol Chem 2012; 287:10013-20; PMID:22318725; http://dx.doi.org/10.1074/jbc.M111.335141
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ding D, Zeng SX, Ye QZ, Lu H. Structure and activity analysis of Inauhzin analogs as novel antitumor compounds that induce p53 and inhibit cell growth. PloS One 2012; 7:e46294; PMID:23115626; http://dx.doi.org/10.1371/journal.pone.0046294
   PubMed Web of Science ®Google Scholar
• Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K, Mo YY. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009; 106:3207-12; PMID:19202062; http://dx.doi.org/10.1073/pnas.0808042106
   PubMed Web of Science ®Google Scholar
• Dai MS, Arnold H, Sun XX, Sears R, Lu H. Inhibition of c-Myc activity by ribosomal protein L11. EMBO J 2007; 26:3332-45; PMID:17599065; http://dx.doi.org/10.1038/sj.emboj.7601776
   PubMed Web of Science ®Google Scholar
• Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987; 328:445-9; PMID:3302722; http://dx.doi.org/10.1038/328445a0
   PubMed Web of Science ®Google Scholar
• Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differe 2010; 17:236-45; PMID:19696787; http://dx.doi.org/10.1038/cdd.2009.109
   PubMed Web of Science ®Google Scholar
• Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell 2009; 35:610-25; PMID:19748357; http://dx.doi.org/10.1016/j.molcel.2009.08.020
   PubMed Web of Science ®Google Scholar
• Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K, Shiekhattar R. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436:740-4; PMID:15973356; http://dx.doi.org/10.1038/nature03868
   PubMed Web of Science ®Google Scholar
• Haase AD, Jaskiewicz L, Zhang H, Laine S, Sack R, Gatignol A, Filipowicz W. TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing. EMBO Rep 2005; 6:961-7; PMID:16142218; http://dx.doi.org/10.1038/sj.embor.7400509
   PubMed Web of Science ®Google Scholar
• Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 2005; 123:607-20; PMID:16271386; http://dx.doi.org/10.1016/j.cell.2005.08.044
   PubMed Web of Science ®Google Scholar
• Gerin I, Bommer GT, McCoin CS, Sousa KM, Krishnan V, MacDougald OA. Roles for miRNA-378/378* in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab 2010; 299:E198-206; PMID:20484008
   PubMed Web of Science ®Google Scholar
• Huang V, Zheng J, Qi Z, Wang J, Place RF, Yu J, Li H, Li LC. Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells. PLoS Genet 2013; 9:e1003821; PMID:24086155; http://dx.doi.org/10.1371/journal.pgen.1003821
   PubMed Web of Science ®Google Scholar
• Challagundla KB, Sun XX, Zhang X, DeVine T, Zhang Q, Sears RC, Dai MS. Ribosomal protein L11 recruits miR-24/miRISC to repress c-Myc expression in response to ribosomal stress. Mol Cell Biol 2011; 31:4007-21; PMID:21807902; http://dx.doi.org/10.1128/MCB.05810-11
   PubMed Web of Science ®Google Scholar
• Liao JM, Zhou X, Gatignol A, Lu H. Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex. Oncogene 2014; 33:4916-23; PMID:24141778; http://dx.doi.org/10.1038/onc.2013.430
   PubMed Web of Science ®Google Scholar
• Frenzel A, Zirath H, Vita M, Albihn A, Henriksson MA. Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. PloS One 2011; 6:e27988; PMID:22132187; http://dx.doi.org/10.1371/journal.pone.0027988
   PubMedGoogle Scholar
• Cole MD. The myc oncogene: its role in transformation and differentiation. Ann Rev Genet 1986; 20:361-84; PMID:3028245; http://dx.doi.org/10.1146/annurev.ge.20.120186.002045
   PubMed Web of Science ®Google Scholar
• Dai MS, Jin Y, Gallegos JR, Lu H. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia 2006; 8:630-44; PMID:16925946; http://dx.doi.org/10.1593/neo.06334
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34; PMID:9529249; http://dx.doi.org/10.1016/S0092-8674(00)81401-4
   PubMed Web of Science ®Google Scholar
• Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999; 1:20-6; PMID:10559859; http://dx.doi.org/10.1038/8991
   PubMed Web of Science ®Google Scholar
• Honda R, Yasuda H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 1999; 18:22-7; PMID:9878046; http://dx.doi.org/10.1093/emboj/18.1.22
   PubMed Web of Science ®Google Scholar
• Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, Mori Y, Raychaudhuri P. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem 2004; 279:36698-707; PMID:15199070; http://dx.doi.org/10.1074/jbc.M312305200
   PubMed Web of Science ®Google Scholar
• Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 2004; 431:712-7; PMID:15361884; http://dx.doi.org/10.1038/nature02958
   PubMed Web of Science ®Google Scholar
• Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 2004; 279:44475-82; PMID:15308643; http://dx.doi.org/10.1074/jbc.M403722200
   PubMed Web of Science ®Google Scholar
• Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 2004; 24:7654-68; PMID:15314173; http://dx.doi.org/10.1128/MCB.24.17.7654-7668.2004
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 2003; 23:8902-12; PMID:14612427; http://dx.doi.org/10.1128/MCB.23.23.8902-8912.2003
   PubMed Web of Science ®Google Scholar
• Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 2003; 3:577-87; PMID:12842086; http://dx.doi.org/10.1016/S1535-6108(03)00134-X
   PubMed Web of Science ®Google Scholar
• Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 2004; 24:7669-80; PMID:15314174; http://dx.doi.org/10.1128/MCB.24.17.7669-7680.2004
   PubMed Web of Science ®Google Scholar
• Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer cells 1990; 2:35-43; PMID:2204382
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M, Lu Y, Leong L, Haedicke K, Scanlon KJ. Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer 1990; 26:383-90; PMID:2141497; http://dx.doi.org/10.1016/0277-5379(90)90238-O
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Wright KA, Rhodes T. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys 1991; 20:217-20; PMID:1846846; http://dx.doi.org/10.1016/0360-3016(91)90093-J
   PubMed Web of Science ®Google Scholar
• Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB. In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 1993; 92:431-40; PMID:8100837; http://dx.doi.org/10.1172/JCI116585
   PubMed Web of Science ®Google Scholar
• Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y, Shibuya M, Terada M, Saijo N. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 1991; 63:237-41; PMID:1997100; http://dx.doi.org/10.1038/bjc.1991.56
   PubMed Web of Science ®Google Scholar
• Sklar MD, Prochownik EV. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res 1991; 51:2118-23; PMID:2009531
   PubMed Web of Science ®Google Scholar
• Mizutani Y, Fukumoto M, Bonavida B, Yoshida O. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994; 74:2546-54; PMID:7923012; http://dx.doi.org/10.1002/1097-0142(19941101)74:9%3c2546::AID-CNCR2820740924%3e3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Liao JM, Lu H. Autoregulatory suppression of c-Myc by miR-185-3p. J Biol Chem 2011; 286:33901-9; PMID:21832077; http://dx.doi.org/10.1074/jbc.M111.262030
   PubMed Web of Science ®Google Scholar
• Sun XX, Dai MS, Lu H. Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11. J Biol Chem 2008; 283:12387-92; PMID:18305114; http://dx.doi.org/10.1074/jbc.M801387200
   PubMed Web of Science ®Google Scholar